New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing MS

 -- 85% of treatment-naïve, early-stage relapsing-remitting multiple

      sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) 
      in open-label Phase IIIb ENSEMBLE study 
 
   -- OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions 
      in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of 
      Phase III ORATORIO study 
 
   -- OCREVUS-treated patients show highest adherence and persistence rates 
      compared with other disease-modifying therapies (DMTs) in two-year U.S. 
      claims analysis 

https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Press-Release-nbsp-New-data-for-Roche-s-OCREVUS-ocrelizumab-reinforce-significant-benefit-on-slo-32983607/